Overcoming regulatory challenges in the development of companion diagnostics for monitoring and safety

Personalized Medicine
Rumiko Shimazawa, Masayuki Ikeda

Abstract

Concurrent development and co-approval of a companion diagnostic (CDx) with a corresponding drug is ideal, but often unfeasible. Because of limited exposure to a drug in clinical trials, crucial information on safety is sometimes revealed only after approval. Therefore, a CDx for monitoring/safety is often developed after approval of a corresponding drug. However, regulatory guidance is insufficient if contemporaneous development is not possible, thereby leaving plenty of opportunities for improvement with respect to pharmacovigilance and retrospective validation of the CDx. Furthermore, global harmonization of guidance on how to incorporate new scientific information from retrospective analyses of biomarkers should lead to the establishment of more evidence for the development of CDx for approved drugs.

References

Apr 12, 2002·Lancet·Seth HetheringtonAllen D Roses
Dec 24, 2003·Thrombosis and Haemostasis·Brian F GageHoward L McLeod
Mar 6, 2004·Clinical Pharmacology and Therapeutics·Farhad KamaliHilary Wynne
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Jul 31, 2004·Pharmacogenetics·Michael A HillmanJames K Burmester
Nov 13, 2004·The Annals of Pharmacotherapy·Amy G CutrellTrevor R Scott
Feb 8, 2008·The New England Journal of Medicine·Simon MallalUNKNOWN PREDICT-1 Study Team
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael SaagUNKNOWN Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team
Apr 25, 2009·International Journal of Clinical Oncology·Masahide OnoueKen-ichi Inui
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sumithra J Mandrekar, Daniel J Sargent
Oct 10, 2009·Health Policy·Lisa M Meckley, Peter J Neumann
Apr 9, 2010·Clinical Pharmacology and Therapeutics·P LenziniB F Gage
Jan 11, 2012·The Pharmacogenomics Journal·J CohenK Manzolillo
May 18, 2012·British Journal of Clinical Pharmacology·Rashmi R Shah, Devron R Shah
Sep 18, 2012·British Journal of Clinical Pharmacology·Rumiko Shimazawa, Masayuki Ikeda
Feb 2, 2013·Nature Reviews. Drug Discovery·Marc MaliepaardMarkus Paulmichl
Apr 26, 2013·The New England Journal of Medicine·Judith A RacoosinDavid R Nielsen
Aug 8, 2013·British Journal of Clinical Pharmacology·Talitha I VerhoefAnke-Hilse Maitland-van der Zee
Sep 7, 2013·Nature Reviews. Drug Discovery·Jane FridlyandHoward I Scher
Nov 21, 2013·The New England Journal of Medicine·Stephen E KimmelUNKNOWN COAG Investigators
Nov 21, 2013·The New England Journal of Medicine·Munir PirmohamedUNKNOWN EU-PACT Group
Jan 11, 2014·Journal of Clinical Pharmacy and Therapeutics·R Shimazawa, M Ikeda
Feb 19, 2014·Pharmacogenomics·Richard Tutton
Mar 19, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sarah K ByronAdrian Newland
Sep 25, 2014·Expert Review of Molecular Diagnostics·Erick LinJian-Bing Fan
Nov 2, 2014·Nature Reviews. Drug Discovery·Arthur L HoldenMatthew R Nelson
Jan 20, 2015·Expert Review of Molecular Diagnostics·Jan Trøst Jørgensen
Feb 24, 2015·Trends in Pharmacological Sciences·Munir PirmohamedMia Wadelius
Mar 1, 2011·Personalized Medicine·Iain MillerAlain Huriez
Jan 1, 2013·Personalized Medicine·Lawrence Lesko

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
PCR

Software Mentioned

CDx

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved